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Abstract
Rift Valley fever phlebovirus (RVFV; Phenuiviridae, Phlebovirus) is an important mosquito-
borne pathogen of both humans and ruminants. The RVFV genome is composed of tripar-
tite, single stranded, negative or ambisense RNAs. The small (S) segment encodes both
the nucleocapsid protein (N) and the non-structural protein (NSs). The N protein is responsi-
ble for the formation of the viral ribonucleoprotein (RNP) complexes, which are essential in
the virus life cycle and for the transcription and replication of the viral genome. There is cur-
rently limited knowledge surrounding the roles of the RVFV nucleocapsid protein in viral
infection other than its key functions: N protein multimerisation, encapsidation of the RNA
genome and interactions with the RNA-dependent RNA polymerase, L. By bioinformatic
comparison of the N sequences of fourteen phleboviruses, mutational analysis, minigenome
assays and packaging assays, we have further characterised the RVFV N protein. Amino
acids P11 and F149 in RVFV N play an essential role in the function of RNPs and are neither
associated with N protein multimerisation nor known nucleocapsid protein functions and
may have additional roles in the virus life cycle. Amino acid Y30 exhibited increased minige-
nome activity despite reduced RNA binding capacity. Additionally, we have determined that
the N-terminal arm of N protein is not involved in N-L interactions. Elucidating the fundamen-
tal processes that involve the nucleocapsid protein will add to our understanding of this
important viral protein and may influence future studies in the development of novel antiviral
strategies.
Author summary
Rift Valley fever phlebovirus (RVFV) remains an ongoing serious socio-economic threat,
and with a lack of widely available licensed vaccines and treatments it is increasingly
important to understand the underlying biology behind RVFV viral replication. Re-analy-
sis of RVFV nucleocapsid, a key protein within the RVFV replication cycle has led to the
characterisation of previously unidentified conserved amino acids. This study increases
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our understanding of the nucleocapsid protein which may play an important role in the
future development of vaccine and antiviral therapies.
Introduction
RVFV is a member of the Phlebovirus genus of the Phenuiviridae family of viruses, in the
Bunyavirales order [1]. The Phlebovirus genus can be broadly split into two distinct groups.
One group pertains to the viruses transmitted by mosquitos or sandflies, commonly referred
to as the Phlebotomine group, of which RVFV is a member. The second group pertains to
viruses transmitted primarily by ticks [2]. The RVFV genome consists of two negative and one
ambisense RNA segment. The large (L) segment encodes the RNA dependent RNA polymer-
ase. The medium (M) segment encodes two non-structural proteins (p78 and NSm) and two
glycoproteins, Gn and Gc [3]. The small (S) segment encodes the nucleocapsid protein (N)
and the non-structural protein (NSs) using an ambisense coding strategy [4]. Each genome
segment is flanked by untranslated regions (UTRs) that are involved in regulating transcrip-
tion and replication of the genome segments. Due to terminal sequence complementarity, the
3’ and 5’ UTRs base pair and generate panhandle structures resulting in the recruitment of the
viral polymerase (L), thus allowing the formation of viral ribonucleoprotein complexes (RNPs)
[5, 6] as is the case for all bunyaviruses [2, 7, 8]. RVFV N protein is a key protein within the
RVFV proteome. It is characterised by a protruding N-terminal arm, an RNA binding cleft
and a multimerisation groove. It has several essential functions that allow the replication and
transcription of the viral genome segments. The N proteins of viruses belonging to the Bunya-
virales order have been shown to function to encapsidate the viral genome which protects the
genetic information from harsh conditions found in the intracellular environment, such as
RNase degradative enzymes [9]. This encapsidation function of the N protein and the forma-
tion of the viral RNP complex allow the binding of the RNA-dependent RNA-polymerase
thereby allowing transcription and replication to take place. Furthermore, N protein forms
multimeric structures in infected cells [10–12]; in the case of RVFV the binding of the N-ter-
minal arm to adjacent N monomers results in the formation of ring-shaped oligomers and
allows the creation of filamentous RNPs required for replication of the viral genome [10].
N proteins of other families in the Bunyavirales order have also been investigated and have
added to our understanding of N protein function. For the related genus Orthohantavirus, the
N protein is thought to have RNA chaperoning activity where it dissociates the viral RNA
duplexes, allowing sequestration of the 5’ end of the RNA and the binding of the L protein [13,
14]. Additionally, Sin Nombre virus (of the genus Hantavirus) N has been shown to bind
mRNA caps, an essential process in cap-snatching [15]. The Bunyavirales order is very broad
and viral N protein structures from different families are often unrelated, as evidenced by the
Crimean-Congo haemorrhagic fever orthonairovirus (CCHFV) N protein. CCHFV is part of
the Orthonairovirus genus within the Nairoviridae family and has a distinct N protein structure
more closely related with the Arenaviridae family compared to other members of the Bunyavir-
ales [16]. In the case of the Peribunyaviridae, the order prototype bunyavirus Bunyamwera
orthobunyavirus (BUNV) nucleocapsid protein has also been shown to encapsidate the viral
genome and carries out largely the same functions as demonstrated for phleboviruses. A previ-
ous mutagenesis study carried out using BUNV identified several residues that impact the rep-
lication efficiency of the virus [17].
Several studies examining RNA binding have identified residues within the core of the
RVFV N protein that are essential for the formation of viral RNPs [10, 18]. The bound RNA
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interacts with 18 conserved residues within the protein core and the hinge region between the
N-terminal arm and the core. In particular, amino acid Y30 is located at the hinge region of
the N-terminal arm and has been shown to stack with the 5’ most RNA base when binding
RNA [19]. Residues R64D, K67D and K74D were predicted to form the RNA binding cleft and
a triple substitution mutant resulted in the loss of RNA binding [10]. The formation of RNPs
requires N monomers to form hexameric ring structures through the binding of the N-termi-
nal arm of one monomer to an adjacent monomers oligomerisation groove [10]. Residues Y3,
L7, I9, P11, V16, I21, W23, V25, F28 and Y30 present on the N terminal arm of the RVFV N
protein are predicted to interact with the oligomerisation groove. Disruption of the oligomeri-
sation groove prevents the formation of higher order N protein structures and thus stops the
formation of the viral RNPs [20]. N protein also has a dimeric closed conformational state
which is predicted to occur in the absence of viral or host RNA [10]. In the presence of RNA,
the conformation opens the N-terminal arm allowing the binding to adjacent subunits form-
ing higher order structures [10]. Several RVFV N protein studies have identified the functions
of named amino acid residues and these are summarized in Table 1 [10, 18–20]. These were
found to be involved in either N multimerisation or RNA binding, and were used as a refer-
ence for selecting the mutants in this study that have been previously unexplored. This study
aimed to widen RVFV N protein research by informing on a number of non-characterized, yet
conserved amino acids found across multiple members of the Phlebovirus genus. As we
believed these to be essential nucleocapsid residues with regards to involvement in important
protein-protein interactions and other functions, we generated a panel of uncharacterised N
protein mutants based on conservation data. These mutant proteins were investigated by uti-
lising minigenome assays, packaging assays as well as biochemical techniques to assess their
relevance in the RVFV life cycle. This analysis revealed that there are still fundamental under-
lying questions regarding the formation of phlebovirus RNP complexes, in particular, regard-
ing residues P11 and F149 that confer loss of function that were not previously described. Our
data add to the understanding of RVFV N and the role(s) of individual conserved amino acids
in replication.
Materials and methods
Cells
BSR-T7/5 cells [21] (obtained from K.-K. Conzelmann, Ludwig-Maxmilians-Universita¨t Mu¨n-
chen, Germany) were grown in Glasgow Minimum Essential Medium (GMEM; Gibco) sup-
plemented with 10% fetal calf serum (FCS), 1% penicillin/streptomycin and the selection agent
G418 at 37˚C with 5% CO2. BSR-T7/5 CL21 cells were generated during this study through
dilution cloning of BSR-T7/5 cells. This clone showed increased T7 RNA polymerase-medi-
ated gene expression.
Plasmids
Plasmids pTM1-N, pTM1-L, pTVT7-GM:hRen and pTM1-FF-Luc have been described previ-
ously [6]. pTM1-N and pTM1-L plasmids contain the RVFV MP12 strain N and L open read-
ing frames (ORF) under the control of a T7 promoter. pTM1-L3V5 has been previously
described [22] and contains a V5 tagged epitope within the L ORF. pTVT7-GM:hRen contains
the humanised Rluc ORF in place of the M polyprotein precursor ORF (still flanked by M
UTRs) in antisense orientation under the control of a T7 promoter. pTM1-FF-Luc expresses
Photinus (FFluc) luciferase and was used as a transfection control in the minigenome assay.
Plasmid p14-N contains the RVFV MP12 strain N ORF with N-terminal 6His-tag attached for
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bacterial expression and purification. The virus-like particle assays were carried out using the
pTM1-based plasmids above, with the addition of pTM1-M.
Sequence alignments
Sequence alignments were performed using CLC-Genomic Workbench using the following
sequences: Punta Toro phlebovirus (Adames) (ABD92922.1); sandfly fever Naples phlebovirus
Table 1. Summary of known RVFV N protein functions. Compiled predicted and known functions of
RVFV N protein from studies focused on uncovering the RNA binding properties of RVFV N. Functional infor-
mation was determined through varied methods, including analysis of RVFV N crystal structure and mutagen-
esis studies [10, 18, 19].
Residue Function
Met1 Contacts Trp125 dimer interface [18]
Tyr3 Project from N terminal arm—interact with hydrophobic groove [10]
Tyr4 Observed loss of dimer formation (destabilisation of helix a1) [18]
Gln5 Contacts Trp125 dimer interface [18]
Leu7 Project from N terminal arm—interact with hydrophobic groove [10]
Ile9 Contacts Trp125 dimer interface, Project from N terminal arm—interact with hydrophobic groove
[10, 18]
Phe11 Observed loss of dimer formation (destabilisation of helix a1), Project from N terminal arm—
interact with hydrophobic groove [10, 18]
Ala12 Intersubunit van der waals contacts [18]
Val16 Project from N terminal arm—interact with hydrophobic groove [10]
Ile21 Project from N terminal arm—interact with hydrophobic groove [10]
Trp24 Project from N terminal arm—interact with hydrophobic groove [10]
Val25 Project from N terminal arm—interact with hydrophobic groove [10]
Phe28 Project from N terminal arm—interact with hydrophobic groove [10]
Tyr30 Project from N terminal arm—interact with hydrophobic groove, Hinge region stacks with 5’most
base in RNA binding (base 1) [10, 19]
Phe33 "Back pocket" of RNA binding slot interacts with base 2 [19]
Arg64 Predicted RNA binding cleft, loss of RNA binding in triple mutant* [10]
Gly65 Interacts with base 5 in narrow pocket [19]
Lys67 Predicted RNA binding cleft, loss of RNA binding in triple mutant* [10]
Lys74 Predicted RNA binding cleft, loss of RNA binding in triple mutant* [10]
Ala109 Lines RNA binding slot interacts with base 3 and 4 [19]
Ala110 Lines RNA binding slot interacts with base 3 and 4 [19]
Val120 Intersubunit van der Waals contacts [18]
Val121 Intersubunit van der Waals contacts [18]
Glu124 Intersubunit van der Waals contacts [18]
Trp125 Contacts Met1, Gln5, Ile9 and Trp125 of second monomer. Critical for dimer formation [18]
Leu126 Interacts with base 5 in narrow pocket [19]
Pro127 Interacts with base 5 in narrow pocket [19]
Thr131 Intersubunit van der Waals contacts [18]
Pro147 Lines RNA binding slot interacts with base 3 and 4 [19]
Phe176 Interacts with base 5 in narrow pocket [19]
Arg178 Forms salt bridge with Ala245 [18]
Ile180 Lines RNA binding slot interacts with base 3 and 4 [19]
Pro199 Lines RNA binding slot interacts with base 3 and 4 [19]
Ala202 Lines RNA binding slot interacts with base 3 and 4 [19]
Ala245 Forms salt bridge with Arg178 [18]
https://doi.org/10.1371/journal.pntd.0006155.t001
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(Namru) (AEL29662.1); Candiru phlebovirus (YP_004347994.; Ixcanal phlebovirus (CA_Ar_1
70897) (AEB70980.1); RVFV (MP12) (AAF00694.1); Salehabad phlebovirus (I-81) (AGA827
43.); Granada phlebovirus (GR25) (ADO17682.1; Toscana phlebovirus (ELB) (ABQ23554.1;
sandfly fever Turkey phlebovirus (Izmir19) (AEB97382.1); Uukuniemi phlebovirus (UUKV)
(S23) (AAA47958.1); Lone Star phlebovirus (TMA1381) (YP_008003509.; Bhanja phlebovirus
(M3811) (AFO66274.1); SFTS phlebovirus (AHZ/China/2011) (AFJ15066.1); Heartland phle-
bovirus (TN) (AIF75091.1).
Site-directed mutagenesis
A QuickChange II Site-Directed Mutagenesis Kit (Agilent Technologies) was used for primer-
specific mutagenesis of the pTM1-N plasmid N ORF as per the manufacturer’s instructions.
The mutants delN1-14, delN1-31, F11A, Y30A, D34A, F149A and N181A were generated
from RVFV MP12 pTM1-N and p14-N.
Minigenome assays
BSR-T7/5 cells were plated at a density of 1x105 cells per well in a 24 well plate. After 24 hours,
cells were transfected with 0.2 μg pTM1-L, 0.5 μg pTVT7-GM:hRen, 25 ng pTM1-FF-Luc and
1 μg pTM1-N or one of the pTM1-N mutant clones using Lipofectamine 2000 transfection
reagent (Life Technologies) according to manufacturer’s instructions. At 24 h post-transfec-
tion cells were lysed in 100 μl passive lysis buffer (Promega). Rluc and FFluc activities were
measured according to the manufacturers’ instructions on a Promega Glomax multidetection
system using Dual-Luciferase Reporter Assay Systems reagents (Promega).
Virus-like particle formation assay
BSR-T7/5 cells were plated at a density of 2 x105 cells per well. After 24 h, cells were transfected
with 0.25 μg pTM1-L, 0.5 μg pTVT7-GM:hRen, 0.5 μg pTM1-M, 25 ng pTM1-FF-Luc and
0.5 μg pTM1-N or one of the pTM1-N mutant clones using LT1 transfection reagent (Life
Technologies) according to manufacturer’s instructions. At 48 hours post-transfection, the
supernatant was removed and treated with 2ul Benzonase nuclease (Merck Millipore) for 4 h
at 37˚C. Of the treated supernatant, 160 μl was subsequently added to a 12-well plate of
BSR-T7/5 cells pre-transfected 24 h prior with 0.5 μg pTM1-N and 0.5 μg pTM1-L. At 24 h
post VLP infection, cells were lysed in 200 μl passive lysis buffer (Promega). Rluc and FFluc
activities were measured as described above.
Immunoblotting
Cell lysates were separated on Bolt 4–12% Bis-Tris Plus (Novex) gradient gels. Proteins were
transferred onto 0.45 μm nitrocellulose membranes (Amersham Protran) using Trans-blot SD
cell (Bio-Rad). The membrane was blocked using PBS containing 0.1% Tween 20 and 5% Mar-
vel milk powder for 1 h at room temperature. The membrane was incubated with either anti-
RVFV N polyclonal rabbit antibody (1:5000) [23] or beta-actin rabbit monoclonal antibody
(1:1000; Cell Signalling Technology) overnight at 4˚C. A horseradish peroxidase (HRP) anti-
rabbit secondary antibody (1:1000) was then applied to the membrane. Pierce ECL Western
Blotting Substrate (Thermo-Scientific) followed by visualisation on a Biorad ChemiDoc system.
Protein expression and purification in Escherichia coli
The p14-N protein expression plasmids for each mutant N protein were transformed into
Rosetta2 (DE3) cells (Novagen). Subsequent colonies were grown in LB Broth to OD0.6–0.8
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before inducing with 1 mM IPTG, and the cells were cultured at 20˚C for overnight expres-
sion. The bacteria were pelleted for 30 min at 3600 x g. The pellet was resuspended in 12 ml
B-PER Complete Bacterial Protein Extraction Reagent (Thermo Scientific) supplemented with
EDTA-free Protease Inhibitor Cocktail (Thermo Scientific) and rotated at room temperature
for 1 h. After lysis, 50 mM Tris pH8.0, 20 mM Imidazole, 0.3 M NaCl, 10% glycerol was added
to the lysate. The lysate was centrifuged at 4400 x g for 30 min at 4˚C and the supernatant was
collected. For each sample, 900 μl of the Ni-NTA resin (Thermo Scientific) was equilibrated
with 50 mM Tris pH8.0, 20 mM imidazole, 0.3 M NaCl, 10% glycerol. The clarified superna-
tants were added to equilibrated Ni-NTA resin tube and incubated at 4˚C with gentle rotation
for 30 min. The samples were then spun at 2000 x g for 1 min and the supernatant removed.
The Ni-NTA resin was washed with buffer containing 50 mM Tris pH8.0, 40 mM imidazole,
0.3 M NaCl, 10% glycerol three times. The protein was eluted with 1.5 ml of elution buffer con-
taining 10 mM Tris pH 8.0, 200 mM imidazole, 0.3 M NaCl and 10% glycerol. Vivaspin 500
Centrifugal Concentrator (Sartorius) was used to exchange the elution buffer for protein stor-
age buffer (10 mM Tris pH8.0, 150 mM NaCl, 10% glycerol) and protein samples were stored
at -80˚C. Purified protein samples were visualised on Bolt 4–12% Bis-Tris Plus (Novex) gradi-
ent gels, stained with InstantBlue Protein Stain (Expedeon).
DSP crosslinking assay
The purified mutant RVFV N proteins were concentrated to 0.2 μg/μl in 25 μl PBS/glycerol
using Vivaspin centrifugal concentrators (Sartorius). Dithiobis(succinimidyl propionate)
(DSP)-Lomants reagent (Thermo Scientific) was added to a final concentration of 1 mM and
gently mixed, then incubated at 20˚C for 40 min. The reaction was stopped by directly adding
protein loading buffer under non-reducing condition and then analysed on a 4–12% Bis-Tris
plus (Novex) gradient gel.
RNA binding assay
Recombinant parental virus (rMP12) and mutant N proteins purified by Ni-NTA were exam-
ined for RNA-binding activity. 10 μg of purified protein was mixed with 2x RNA gel loading
buffer (Thermo Scientific) containing 95% formamide. The RNA was separated on the 2%
TopVision Agarose gel (Thermo Scientific) in TBE buffer stained with Gel Red (Biotium) and
visualised by UV.
Immunoprecipitation
BSRT-7/5 CL21 cells were seeded into 6-well plates at 4.8 x105 cells per well. Each well was
transfected with 3 μg pTM1-N or a mutant pTM1-N and 2 μg pTM1-L3V5 expression plas-
mids. After 24 h, cells are lysed with lysis buffer containing 20 mM Tris pH 7.5, 150 mM NaCl,
5 mM MgCl2, 0.5% Triton X-100, and Halt Protease inhibitor cocktail (Thermo Scientific) and
10 μg RNase (Thermo Scientific). The lysate was kept on ice for 20 min then centrifuged at
16000 x g for 20 min to pellet the cellular debris. Protein A beads were bound with anti-V5
antibody (#27671, Abcam). Lysates were rotated with beads for 2 h, after which, the beads
were washed three times with lysis buffer and eluted by heating the sample to 90˚C in LDS
Sample buffer and 2-mercaptoethanol reducing agent (Thermo Scientific). Samples were ana-
lysed by western blotting with primary anti-RVFV N antibody (1:5000) or anti-V5 antibody
(1:2000) and secondary HRP-conjugated anti-rabbit (1:1000) or Veriblot anti-IgG (1:1000)
and processed as described for immunoblotting.
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Results
N protein conservation and mutagenesis
Fourteen Phlebovirus nucleoprotein sequences available from Genbank were aligned (Fig 1)
and conserved residues were identified between all phleboviruses, between phleboviruses
thought to be transmitted by an insect vector or phleboviruses transmitted by ticks. Of the con-
served residues identified, five amino acids were selected for alanine substitution studies. Resi-
dues Y30 (previously analysed), D34, F149 and N181 in N protein sequences were found to be
conserved across the whole Phlebovirus genus, derived from viruses transmitted by both insect
and ticks. Residue F11, also previously analysed, is highly conserved between the mosquito-
borne phleboviruses, with the exception of CDUV, but often substituted with an isoleucine
within the UUKV-like tick-borne virus group.
The ambisense coding strategy of the Phlebovirus S segment results in differential expres-
sion of both the N protein and the non-structural protein NSs [9]. To evaluate the importance
of these highly conserved N residues in isolation, without any interference of NSs on N protein
or minigenome activity [22], an expression plasmid system containing only the N protein
open reading frame (pTM1-N) was used over plasmids that express cDNA copies of the viral S
segment RNA. The two N-arm mutants, a deletion of the amino acids 1–14 and 1–31, their
location modelled in Fig 2, were also introduced to our panel of N protein mutants to examine
the impact of N-N multimer interactions on N protein functions.
Functional ribonucleoprotein complexes mediate the transcription and replication of the
viral genome. This study aimed to assess the importance of the conserved residues identified
from our phlebovirus N protein alignments. This was achieved using a previously described
minigenome system, in which a virus genome segment analogue, where the viral coding
sequence has been replaced with Rluc leaving the viral M segment UTRs intact, is transfected
into T7 RNA polymerase expressing cells along with plasmids expressing the L protein and
our N protein mutants [6, 24]. As seen in Fig 3A, the two N-arm mutants, delN1-14 and
delN1-31 showed no activity in the minigenome system. Interestingly, the residues examined
that were highly conserved within the Phlebovirus genus showed a range of activities. Mutants
F11A and F149A had no replication activity, mutant D34 showed a decreased activity
Fig 1. Alignment of Phlebovirus sequences highlighting point mutations. Rift Valley fever phlebovirus (RVFV), Toscana phlebovirus (TOSV), sandfly
fever Naples phlebovirus (SFNV), sandfly fever Turkey phlebovirus (SFTV), Salehabad phlebovirus (SALV), Candiru virus (CDUV), Granada phlebovirus
(GRV), Heartland phlebovirus (HRTV), Ixcanal phlebovirus (IXCV), Punta Toro phlebovirus (PTV), SFTS phlebovirus (SFTSV), Uukuniemi phlebovirus
(UUKV), Lone Star phlebovirus (LSV), Bhanja phlebovirus (BHAV) sequences were aligned and conserved regions identified. The position of amino acids
is relative to the RVFV nucleocapsid sequence. Tick-borne phleboviruses have been highlighted.
https://doi.org/10.1371/journal.pntd.0006155.g001
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compared to wildtype (WT) N and mutants Y30A and N181A showed a significantly increased
activity. Previous mutagenesis studies of BUNV N protein suggested that inconsistent protein
expression levels may have significant effects on minigenome system activity [17]. As such a
western blot for N protein was carried out using the cell lysates from the minigenome assay to
control the expression levels of N protein. Expression levels of N protein were largely consis-
tent between different transiently transfected N mutants (Fig 3B), except arm mutant delN1-
31 which showed a greatly reduced expression level and was detected by using a BSR-T7/5
clone with higher T7 RNA polymerase activity produced during this project (S1 Fig).
RNA binding properties of N protein mutants
RVFV N protein has two key functions; encapsidation of the viral RNA and multimerisation
to allow for the formation of the viral RNPs [10, 18, 19]. To determine if the RNA binding
capacity of the mutant panel was impaired, we carried out an RNA binding assay on purified
mutant N proteins (Fig 4A). For this we used the viral N protein’s ability to bind non-specifi-
cally bacterial RNA, which occurs before and during the protein purification process, as
shown previously [18, 25]. To determine whether this function was impaired, RNA was disso-
ciated from the purified N protein using formamide-containing RNA loading buffer [25]. As
shown in Fig 4B, RNA binding activity was observed in the majority of mutant N proteins
examined. However, neither the arm mutant delN1-31 nor mutant Y30A had detectable RNA
Fig 2. Chimera 3D Model of RVFV N protein monomeric structure with mutated residues highlighted (PDB: 3LYF) [18]. (A) RVFV N protein with
highlighted point mutations (top image) and corresponding surface view (lower image). (B) Alternative orientation of the RVFV N protein point mutations
at a 90-degree offset to (A). (C) N protein with highlighted N-terminal arm position 1–14 in red, 15–31 in blue. (D) Mutant RVFV N protein with the full
delN1-31 arm removed and surface view.
https://doi.org/10.1371/journal.pntd.0006155.g002
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bound to mutant N protein when purified, which was consistent with our measurement of
260/280 ratio for all these proteins.
Multimerisation properties of N proteins
The N protein of the Smithburn vaccine strain of RVFV was shown to form higher order struc-
tures: tetramers, pentamers and hexamers in multiples of the 27 kDA monomer [10]. Here we
assessed whether the minigenome activities observed previously resulted from changes in the
multimerisation. The multimerisation properties of the mutant N proteins panel were deter-
mined through a DSP crosslinking assay on purified N protein from a bacterial expression sys-
tem. Only the delN1-31 mutant showed a reduced capacity to multimerise and all other
mutants showed multimerisation capacity similar to WT N protein (Fig 4C).
Interactions of N and L proteins
The ability for the N protein to interact with the viral L protein is important for the formation
of replication-active RNP complexes. By using a construct expressing a V5-tagged L protein
(L3V5) [22], we were able to perform co-immunoprecipitation (co-IP) studies to assess the
interaction of L protein with our panel of mutant N proteins. The co-IP was performed under
Fig 3. Effect of N protein mutations on RVFV-derived minigenome activity. BSR-T7/5 cells were
transfected with pTM1-N (wildtype [WT] N, mutant N) or empty plasmid as negative control (Con) expressing-
plasmids, pTM1-L, pTVT7-GM:hRen as well as pTM1-FF-Luc as a transfection control. (A) Values of triplicate
experiments presented were calculated by dividing Rluc activity by FFluc luciferase activity to normalise
differences in transfection efficiency; * denotes p<0.05, ** for p<0.001 using Student’s T-test. (B) Western
blot of cell lysate probed with RVFV anti-N antibody (top panel) and anti-actin (bottom panel) as loading
control.
https://doi.org/10.1371/journal.pntd.0006155.g003
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RNase conditions to reduce the effect of bound RNA influencing the interaction, though RNA
bound within N protein prior to co-IP would not be removed in these conditions. Following
co-IP with an anti-V5 antibody, western blotting with anti-N and anti-V5 sera was performed
to identify if N protein co-immunoprecipitated with the L protein. The mutants found to be
functional in the minigenome system (Y30A, D34A and N181A) interacted with the L protein.
Intriguingly, N mutants’ delN1-14, delN1-31 and F11A and F149A could also bind to the L
protein despite not being active in the minigenome assays (Fig 5). This suggested that any
functional deficiencies observed are not due to absence of direct interactions between the rep-
lication complex proteins, though L polymerase processivity could be affected.
Fig 4. RVFV N protein binding properties as determined by binding of bacterial RNA during the
purification process and multimerisation properties of N proteins. (A) InstantBlue stained gel of purified
N proteins used in this study. (B) The in vitro RNA binding activity of WT and mutant N proteins as indicated
was determined by observing the quantity of RNA dissociated after treatment with RNA loading buffer
containing formamide representative of three repeats; 260/280 Ratios for this experiment are indicated. (C)
Cross-linking was used to determine the formation of N multimers, and purified mutant proteins were cross-
linked as described in Materials and methods, and analysed by western blot with RVFV anti-N antibodies. β-
mercaptoethanol was added to the control (WT R) to reduce the di-sulfide bonds after multimerisation. This
image is representative of three repeats.
https://doi.org/10.1371/journal.pntd.0006155.g004
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Impact of N mutations on packaging and virus-like particle (VLP)
formation
Amongst other functions, RVFV N protein has been implicated in an interaction with the first
30 amino acids of the cytoplasmic tail of the viral glycoprotein Gn to mediate efficient packag-
ing of viral RNP complexes into newly forming virus particles [26]. To determine if any of the
mutated amino acids of N protein abrogated packaging, we employed an assay based on pack-
aging of a minigenome segment into VLPs. Briefly, BSR-T7/5 CL21 cells were transfected with
a RVFV M segment based humanised Rluc minigenome-encoding plasmid (pTVT7-GM:
hRen), plasmids encoding the L protein and WT N protein or one of the mutant N proteins,
and a FFluc expressing plasmid as a transfection control. The transfection mixes were also sup-
plemented with expression plasmid encoding the RVFV M segment glycoprotein precursor.
At 48 h post transfection, the cell culture media of the donor cells (cells used to generate VLPs)
was clarified by centrifugation and nuclease treated to prevent plasmid carry over. Subse-
quently the nuclease-treated VLP containing supernatant was used to inoculate recipient
BSR-T7/5 CL21 cells transiently transfected with plasmids expressing the RVFV L protein and
WT N protein. In the case of functional packaging of the minigenome segment into virions,
the encapsidated pTVT7-GM:hRen is delivered to the recipient cell by the VLP where it is rep-
licated, transcribed and translated resulting in Rluc expression (Fig 6). The VLP assay data cor-
roborated with the minigenome data presented in Fig 3A, showing that only mutants Y30A,
D34A and N181A that were functional in the minigenome system also could form functional,
minigenome containing VLPs.
Discussion
In this study, we sought to gain a greater understanding of the biology and functions of the
RVFV N protein through the identification of amino acids that are highly conserved among
phleboviruses and that have yet unknown functions. RVFV N is a very highly conserved pro-
tein in nature as evidenced by multiple sequence alignment of different isolates, and as such
there is a higher propensity of conserved residues to confer significant function. Of the con-
served residues identified, both F11A and F149A had unidentified roles which appeared essen-
tial for the replication or transcription of viral RNPs and/or formation of RNP complexes. The
F149A mutant showed no activity in minigenome assay and has not been previously described
in the literature. We hypothesise that due to this amino acid being surface exposed within a
protein cleft found in the N protein structure, it may be involved in the binding of host factors
Fig 5. Interaction of L3V5 viral polymerase with WT and mutant N proteins. BSR-T7/5 CL21 cells were
transfected with mutant or WT pTM1-N and pTM1-L3V5. Negative control was transfected pTM1-N without
pTM1-L3V5 (Con). After 24 hours, cells were lysed and the lysate was applied to magnetic beads carrying V5
antibody. The bound L protein was dissociated from the beads and analysed by western blot. The proteins
were fractionated on a 4–12% Bis-Tris plus (Novex) gel and transferred to a nitrocellulose membrane.
Subsequently the blot was probed with anti-V5 antibody and RVFV anti-N antibodies and visualised using
LI-COR. This image is representative of three repeats.
https://doi.org/10.1371/journal.pntd.0006155.g005
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required for these processes. A F11G mutant has previously been shown to be involved in loss
of N-N dimer formation, by a different assay system and using GST-fused N protein, through
the potential misfolding of the N-terminal region and disruption of the N-N interaction [20].
Interestingly here we show that purified F11A mutant protein of RVFV N was still able to
form dimers and higher order structures within our multimerisation assay system. This dis-
crepancy may be explained by the glycine substitution resulting in a less stable structure.
While it is clear that the F11 residue is essential for N protein function, it may be involved in
other interactions relevant for replication other than the ascribed N-N dimer formation or
interactions. These could involve, for example, processivity of RNA synthesis or specific inter-
actions with host factors that are required for virus replication.
We also identified two residues, Y30 and N181, which showed increased activity in the
minigenome system (Fig 3). The residue N181 has no previously described function, but the
N181A mutant was also able to form functional virions in the VLP assay system (Fig 6). Y30A
was considered to be essential in a previous study [19].
Despite evidence that Y30 is an essential residue within the N-terminal arm, involved in the
multimerisation of N protein and the base stacking of RNA within the RNA binding groove,
the Y30A mutant used in this study only appeared to have reduced RNA binding capacity but
retained the ability to form multimers. This corroborated with a previous study indicating that
the Y30A mutant did not disrupt N-N interactions [20]. This reduced RNA binding capacity
of Y30A did not negatively affect the overall expression of the minigenome reporter gene or
packaging into VLPs. There may be an inverse relationship between minigenome activity and
RNA binding, it has been proposed that N may non-specifically bind mRNA preventing trans-
lation however luciferase transfection control levels showed no significant change in the pres-
ence of N (S2 Fig). A mutational analysis of UUKV, also of the Phlebovirus genus, observed
that the Y30A mutant still had activity in a minigenome reporter assay [27]. However, in the
Katz et al. study, further analysis of RNA binding was not carried out. It is possible that the
Fig 6. Activity of RVFV N protein mutants in a VLP assay. BSR-T7/5 CL21 cells were transfected with
pTM1-L, pTVT7-GM:hRen, pTM1-M, pTM1-FF-Luc and mutant or WT pTM1-N as described. Negative
control cells were transfected with full complement of plasmids without pTM1-N (Con). After 48 hours, the
supernatant was harvested and Benzonase treated. The treated supernatant was applied to BSR-T7/5 CL21
cells transfected 24 hours prior with pTM1-N and pTM1-L. Rluc activity was measured at 24 h post-infection.
Experiments were carried out in triplicate and repeated three times.
https://doi.org/10.1371/journal.pntd.0006155.g006
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reduced RNA binding capacity may positively affect RNA replication at the loss of protection
from degradation, however this requires further study. The formation of functional VLPs also
shows that the Y30A mutant still interacts with the Gn glycoprotein to successfully package the
reporter construct.
Both the delN1-14 and delN1-31 N protein mutants showed no activity in the minigenome
assay. UUKV N N-terminal mutants also showed no activity in minigenome-based assays ana-
lysed by the detection of CAT signal. These data support the hypothesis that the N-terminal
arm of phleboviral N proteins are functionally essential [27]. However, the delN1-14 mutant N
protein was still able to form higher order multimers and bound RNA. Based on our RNA-
binding and multimerisation analysis data, it suggests that N protein is still able to efficiently
multimerise and bind RNA without the 1st helix of its N-arm, these functions are impaired if
the second helix of the arm is also removed. However, if the whole arm was removed, oligo-
meric structures were still formed, although at a very low efficiency, suggesting that there is
another mechanism or region involved in N-N binding. Comparatively, a delN1-19 mutant in
UUKV N showed approximately 25% N-N binding capacity indicating that binding was still
occurring at reduced levels [27]. It is possible that the loss of function is due to the impaired
ability of the RNA-dependent RNA-polymerase L to track along the viral RNP and/or due to
the formation of N protein monomers in an incorrect configuration. The lack of activity found
in minigenome assays with delN1-31 N mutant is likely due to its inability to form higher
order structures and bind viral RNA, though the ability for delN1-31 mutant to interact with L
also indicates that the N-terminal arm is not involved in the direct interaction between RNA-
dependent RNA polymerase and viral nucleocapsid protein.
In summary, this study expands the number of known essential residues of RVFV N protein
that are conserved across phleboviruses, while also informing that other residues may have
additional or different functions than previously documented in RVFV. The availability of
protein residue information is an important resource for further studies into the functions and
potential therapeutic targets of RVFV N protein. The conserved nature of these residues in N
proteins also may indicate conserved functions or interactions across the whole Phlebovirus
genus and thus provide important information beyond what we currently understand for
RVFV.
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S1 Fig. Relative expression levels of delN1-31 mutant. Western blot of pTM1 N and delN1-
31 mutant expression in BSR-T7/5 CL21 cells. Extracts of four times more cells transfected
with delN1-31 were loaded for expression analysis.
(TIF)
S2 Fig. Effect of N protein on luciferase expression. Firefly luciferase (FFluc) values for the
experiment described in Fig 3. Values of triplicate experiments presented. Student’s T-test was
performed and determined there was no significance between results.
(TIF)
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